Search research articles
Contact Us
Filters
Showing results (1-10 of 103) with videos related to
Page
of 11
Sort By:
Seminars in Oncology
|
May 31, 2003
Treatment of cancer-related hypercalcemia: the role of gallium nitrate
Brian Leyland-Jones
Clinical Advances in Hematology & Oncology : H&O
|
February 13, 2014
The safety of erythropoiesis-stimulating agents in cancer patients
Brian Leyland-Jones
Seminars in Oncology
|
July 26, 2002
Evidence for erythropoietin as a molecular targeting agent
Brian Leyland-Jones
The Lancet. Oncology
|
August 7, 2003
Breast cancer trial with erythropoietin terminated unexpectedly
Brian Leyland-Jones,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
Brian Leyland-Jones
The Journal of Supportive Oncology
|
December 21, 2004
Treating cancer-related hypercalcemia with gallium nitrate
Brian Leyland-Jones
The Lancet. Oncology
|
March 21, 2002
Trastuzumab: hopes and realities
Brian Leyland-Jones
Journal of the National Cancer Institute
|
July 18, 2013
Erythropoiesis stimulating agents: a personal journey
Brian Leyland-Jones
Cancer Genomics & Proteomics
|
September 20, 2007
Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment
Mark Abramovitz, Brian Leyland-Jones
Lancet (London, England)
|
January 16, 2004
Erythropoietin to treat anaemia in patients with head and neck cancer
Brian Leyland-Jones, Salaheddin Mahmud
Page
of 11
Search research articles
Search
Showing results (1-10 of 103) with videos related to
Sort By:
Page
of 11
Seminars in Oncology
|
May 31, 2003
Treatment of cancer-related hypercalcemia: the role of gallium nitrate
Brian Leyland-Jones
Clinical Advances in Hematology & Oncology : H&O
|
February 13, 2014
The safety of erythropoiesis-stimulating agents in cancer patients
Brian Leyland-Jones
Seminars in Oncology
|
July 26, 2002
Evidence for erythropoietin as a molecular targeting agent
Brian Leyland-Jones
The Lancet. Oncology
|
August 7, 2003
Breast cancer trial with erythropoietin terminated unexpectedly
Brian Leyland-Jones,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2009
Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
Brian Leyland-Jones
The Journal of Supportive Oncology
|
December 21, 2004
Treating cancer-related hypercalcemia with gallium nitrate
Brian Leyland-Jones
The Lancet. Oncology
|
March 21, 2002
Trastuzumab: hopes and realities
Brian Leyland-Jones
Journal of the National Cancer Institute
|
July 18, 2013
Erythropoiesis stimulating agents: a personal journey
Brian Leyland-Jones
Cancer Genomics & Proteomics
|
September 20, 2007
Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment
Mark Abramovitz, Brian Leyland-Jones
Lancet (London, England)
|
January 16, 2004
Erythropoietin to treat anaemia in patients with head and neck cancer
Brian Leyland-Jones, Salaheddin Mahmud
Page
of 11